Comparative metabolism of a new antileishmanial agent, allopurinol riboside, in the parasite and the host cell.
HPP-Rib is a potent antileishmanial agent, which has been useful in defining new and unusual purine metabolizing pathways in leishmaniae, in comparison with those in the host. The ribosyl linkage both in the parasite and in the host is resistant to cleavage. In the parasite there is a selective and marked conversion of HPP-Rib to HPP-Rib-5'-P and 4-APP ribonucleotides as well as incorporation into RNA, which does not occur in the host. These findings with HPP-Rib suggest a new chemotherapeutic approach which may be exploited in the treatment of leishmaniasis.
D000493:Allopurinol / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D000981:Antiprotozoal Agents; D007891:Leishmania / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism*; D012263:Ribonucleosides / Q000378:metabolism* / Q000494:pharmacology; D012265:Ribonucleotides / Q000096:biosynthesis; D013045:Species Specificity
D000981:Antiprotozoal Agents; D012263:Ribonucleosides; D012265:Ribonucleotides; D000493:Allopurinol; C021958:allopurinol riboside